Canadian regenerative medicine company Morphocell Technologies announced the completion of its $50 million Series A financing following a $10 million financing extension add-on.
The initial $40 million Series A round, closed in February 2024, was led by Genson Capital. The recent add-on was led by Investissement Québec, the province’s leading economic development corporation, and CDP Venture Capital, part of Italy’s Cassa Depositi e Prestiti group.
The financing will enable Morphocell to advance its tissue-engineered therapies for patients living with liver disease. It will also facilitate the establishment of Morphocell’s first European subsidiary, in Italy.
Montreal-based Morphocell is a developing stem cell–derived tissue and organ replacement therapies. Its proprietary iPSC-derived platform supports a broad pipeline of tissue-engineered solutions targeting severe organ dysfunctions, with liver disease as its first focus.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!